Cargando…

Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study

Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yun, Yang, Qing-qing, Zhuo, Lin, Yang, Kun, Kou, Hao, Gao, Su-yu, Hu, Wen, Jiang, Qiao-li, Li, Wen-jing, Wu, Dong-fang, Sun, Feng, Cheng, Hong, Zhan, Siyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582747/
https://www.ncbi.nlm.nih.gov/pubmed/36274736
http://dx.doi.org/10.3389/fmicb.2022.1013038
_version_ 1784812911612395520
author Lu, Yun
Yang, Qing-qing
Zhuo, Lin
Yang, Kun
Kou, Hao
Gao, Su-yu
Hu, Wen
Jiang, Qiao-li
Li, Wen-jing
Wu, Dong-fang
Sun, Feng
Cheng, Hong
Zhan, Siyan
author_facet Lu, Yun
Yang, Qing-qing
Zhuo, Lin
Yang, Kun
Kou, Hao
Gao, Su-yu
Hu, Wen
Jiang, Qiao-li
Li, Wen-jing
Wu, Dong-fang
Sun, Feng
Cheng, Hong
Zhan, Siyan
author_sort Lu, Yun
collection PubMed
description Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID-19) patients. To study the association between ambroxol use and clinical outcomes among hospitalized patients of COVID-19 infection. We conducted a multicenter retrospective cohort study involving 3,111 patients with confirmed SARS-CoV-2 infection from three hospitals in Wuhan from 19 December 2019 to 15 April 2020, and the primary outcome was in-hospital mortality. COVID-19 patients were classified into ambroxol and non-ambroxol groups based on the administration of ambroxol during hospitalization. Two analyses including propensity score matching (PSM) to obtain a 1:1 balanced cohort and logistic regression were used to control for confounding factors. The average age of 3,111 patients was 57.55 ± 14.93 years old, 127 of them died during hospitalization, and 924 of them used ambroxol. Treatment with ambroxol did not have a significant effect on in-hospital mortality of COVID-19 patients when compared with non-ambroxol in PSM model after adjusting for confounders (8.0% vs. 3.5%, adjusted OR, 1.03 [95% CI, 0.54–1.97], p = 0.936). Adverse events such as nausea/vomiting, headache, and rash were comparable between the two groups. Our results suggest that the use of ambroxol is not significantly associated with in-hospital mortality in COVID-19 patients, which provides evidence for evaluating the effects of ambroxol on COVID-19 patient outcomes and may be helpful for physicians considering medication alternatives for COVID-19 patients.
format Online
Article
Text
id pubmed-9582747
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95827472022-10-21 Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study Lu, Yun Yang, Qing-qing Zhuo, Lin Yang, Kun Kou, Hao Gao, Su-yu Hu, Wen Jiang, Qiao-li Li, Wen-jing Wu, Dong-fang Sun, Feng Cheng, Hong Zhan, Siyan Front Microbiol Microbiology Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID-19) patients. To study the association between ambroxol use and clinical outcomes among hospitalized patients of COVID-19 infection. We conducted a multicenter retrospective cohort study involving 3,111 patients with confirmed SARS-CoV-2 infection from three hospitals in Wuhan from 19 December 2019 to 15 April 2020, and the primary outcome was in-hospital mortality. COVID-19 patients were classified into ambroxol and non-ambroxol groups based on the administration of ambroxol during hospitalization. Two analyses including propensity score matching (PSM) to obtain a 1:1 balanced cohort and logistic regression were used to control for confounding factors. The average age of 3,111 patients was 57.55 ± 14.93 years old, 127 of them died during hospitalization, and 924 of them used ambroxol. Treatment with ambroxol did not have a significant effect on in-hospital mortality of COVID-19 patients when compared with non-ambroxol in PSM model after adjusting for confounders (8.0% vs. 3.5%, adjusted OR, 1.03 [95% CI, 0.54–1.97], p = 0.936). Adverse events such as nausea/vomiting, headache, and rash were comparable between the two groups. Our results suggest that the use of ambroxol is not significantly associated with in-hospital mortality in COVID-19 patients, which provides evidence for evaluating the effects of ambroxol on COVID-19 patient outcomes and may be helpful for physicians considering medication alternatives for COVID-19 patients. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582747/ /pubmed/36274736 http://dx.doi.org/10.3389/fmicb.2022.1013038 Text en Copyright © 2022 Lu, Yang, Zhuo, Yang, Kou, Gao, Hu, Jiang, Li, Wu, Sun, Cheng and Zhan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Lu, Yun
Yang, Qing-qing
Zhuo, Lin
Yang, Kun
Kou, Hao
Gao, Su-yu
Hu, Wen
Jiang, Qiao-li
Li, Wen-jing
Wu, Dong-fang
Sun, Feng
Cheng, Hong
Zhan, Siyan
Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study
title Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study
title_full Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study
title_fullStr Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study
title_full_unstemmed Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study
title_short Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study
title_sort ambroxol for the treatment of covid-19 among hospitalized patients: a multicenter retrospective cohort study
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582747/
https://www.ncbi.nlm.nih.gov/pubmed/36274736
http://dx.doi.org/10.3389/fmicb.2022.1013038
work_keys_str_mv AT luyun ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT yangqingqing ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT zhuolin ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT yangkun ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT kouhao ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT gaosuyu ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT huwen ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT jiangqiaoli ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT liwenjing ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT wudongfang ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT sunfeng ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT chenghong ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy
AT zhansiyan ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy